Table 1.
Patient characteristics
| Variable | TaTME total group (n = 30) | TaTME questionnaire completer (n = 17) |
|---|---|---|
| Demographic | ||
| Age (yr) | 65.5 ± 9.0 | 67.2 ± 7.0 |
| Males | 24 (80.0) | 12 (70.6) |
| Body mass index (kg/m2) | 25.6 (23.5–27.8) | 25.6 (23.3–28.9) |
| ASA PS classification | ||
| I | 6 (20.0) | 3 (17.6) |
| II | 21 (70.0) | 12 (70.6) |
| III | 3 (10.0) | 2 (11.8) |
| Follow-up oncological results (mo) | 23.0 (17.0–29.3) | - |
| Follow-up of questionnaires (mo) | - | 20.0 (13.0–23.0) |
| Stoma status at time of questionnaires | ||
| Never had a stoma | 4 | 4 |
| Temporary stoma, already closed | 19 | 11 |
| Stoma still present | 7 | 2 |
| Tumor characteristic | ||
| Tumor heighta from anal verge (cm) | 4.0 (2.0) | 4.0 (2.8) |
| Height of the anastomosis from anal verge (cm) | ||
| 0–5.0 | 24 (80.0) | 13 (76.5) |
| 5.1–10.0 | 6 (20.0) | 4 (23.5) |
| Clinical TNM stageb | ||
| T1 | 0 (0) | 0 (0) |
| T2 | 11 (36.7) | 7 (41.2) |
| T3 | 17 (56.7) | 8 (47.1) |
| T4 | 2 (6.7) | 2 (11.8) |
| N0 | 18 (60.0) | 11 (64.7) |
| N1 | 7 (23.3) | 4 (23.5) |
| N2 | 4 (13.3) | 1 (5.9) |
| N3 | 1 (3.3) | 1 (5.9) |
| M0 | 24 (80.0) | 13 (76.5) |
| Mx | 6 (20.0) | 4 (23.5) |
| ypTNM stage, no metastasis | ||
| pT0 | 3 (10.3) | 2 (11.8) |
| pT1 | 5 (17.2) | 2 (11.8) |
| pT2 | 11 (37.9) | 6 (35.3) |
| pT3 | 10 (34.5) | 7 (41.2) |
| N0 | 22 (75.9) | 11 (64.7) |
| N1 | 5 (17.2) | 5 (29.4) |
| N2 | 2 (6.9) | 1 (5.9) |
| Presence of pathologically assessed EMVI | 2 (6.7) | 1 (5.9) |
| Presence of pathologically assessed lymph-invasion | 2 (6.7) | 2 (11.8) |
| Additional therapy | ||
| Neoadjuvant | 14 (46.7) | 9 (52.9) |
| Short course radiotherapy, 5 × 5 Gy | 7 (23.3) | 5 (29.4) |
| Chemoradiationc | 7 (23.3) | 4 (23.5) |
| Adjuvant chemotherapy | 0 (0) | 0 (0) |
Values are presented as mean±standard deviation, number (%), median (interquartile range), or number only.
TaTME, transanal total mesorectal excision; ASA, American Society of Anesthesiologists; PS, physical status; yp, postneoadjuvant pathologic stage; EMVI, extramural vascular invasion.
a
Tumor height assessed by magnetic resonance imaging.
b
Clinical T-stadia that were reported as T1–2 were classified as T2.
c
Chemoradiation consisted of 25×2 Gy radiotherapy and capecitabine of 825 mg/m2 twice a day.